1.  Orforglipron after Wegovy or Zepbound.

ATTAIN-MAINTAIN found that patients transitioned from tirzepatide or semaglutide to oral orforglipron (Foundayo) maintained substantially more of their prior weight reduction than patients switched to placebo. A new option in the maintenance discussion.
https://belite.com/orforglipron-maintenance-after-wegovy-zepbound/

2. CagriSema vs. Zepbound.

CagriSema delivered 23% average weight loss in its head-to-head trial — but did not prove non-inferior to tirzepatide (25.5%). It remains under FDA review, with a decision expected late 2026. What both numbers mean for patients.
https://belite.com/cagrisema-redefine-trials-weight-loss/

3. What the new GLP-1 pill changes.

Foundayo (orforglipron), approved in April, is the first GLP-1 pill with no food or water restrictions — and it joins the oral Wegovy pill as a second, very different oral option.
https://belite.com/foundayo-oral-glp-1-orforglipron-weight-management/

 

Related reading: our existing guides to protecting muscle during GLP-1 therapy and managing GLP-1 side effects and nutrition.

Muscle guide: https://belite.com/glp-1-muscle-loss-lean-mass-protein-strength-training/ — “How Much Muscle Do You Lose on GLP-1 Medications?” (published Aug 4)

Side effects: https://belite.com/side-effects-of-zepbound-what-you-need-to-know-before-starting-treatment/

Nutrition/protein: https://belite.com/how-to-maximize-weight-loss-success-for-patients-on-zepbound-or-wegovy/ — the protein-first eating guide

Clinical Pearl of the Week

Maintenance planning should begin before goal weight. The expanding range of oral and injectable options means long-term treatment can increasingly be individualized rather than treated as an all-or-nothing decision.

Myth vs. Fact

Myth: The less a patient eats on a GLP-1 medication, the better the treatment is working.

Fact: Excessive appetite suppression can compromise protein and micronutrient intake. Effective treatment should produce sustainable fat loss while preserving nutrition, strength, and function.

Questions we are watching

• Can oral maintenance preserve injectable-associated weight loss over several years?
• Will the FDA approve CagriSema late this year, and how will REDEFINE 4 shape its positioning?
• Which patients can safely use lower-dose or extended-interval maintenance?
• Which protein and resistance-training strategies best preserve muscle in older adults?
• How will higher-dose CagriSema and other multi-pathway therapies compare with established treatments?

Bottom line

CagriSema — a once-weekly combination of cagrilintide (an amylin analogue) and semaglutide (a GLP-1 receptor agonist) — validated the multi-pathway approach with roughly 20% or greater average weight loss versus placebo in REDEFINE 1, along with clinically meaningful blood-pressure reductions. But in REDEFINE 4, the open-label head-to-head against tirzepatide (Zepbound), CagriSema did not meet its primary endpoint of non-inferiority: 23.0% average weight loss versus 25.5% with tirzepatide at 84 weeks. CagriSema is not yet FDA-approved; the application is under review with a decision expected late 2026.

Current regulatory status

CagriSema is investigational in the United States. Novo Nordisk filed its New Drug Application on December 18, 2025, based on the placebo-controlled REDEFINE 1 trial, and the FDA is expected to issue a decision in late 2026. It is not available outside clinical trials.

How CagriSema is different

Semaglutide is a GLP-1 receptor agonist. Cagrilintide is a long-acting amylin analogue. CagriSema combines these two satiety pathways in an effort to produce greater weight reduction than either component alone — part of the broader shift from single-pathway medications toward combination and multi-receptor approaches.

What REDEFINE 1 found (vs. placebo)

The Phase 3a, 68-week REDEFINE 1 trial randomized 3,417 adults with obesity, or overweight plus an obesity-related complication, without diabetes, to CagriSema, semaglutide alone, cagrilintide alone, or placebo, alongside lifestyle intervention. CagriSema produced mean weight reduction exceeding 20% at 68 weeks, versus roughly 3% with placebo — establishing that the amylin-plus-GLP-1 combination adds meaningfully to GLP-1 biology alone. The primary results were published in the New England Journal of Medicine in 2025.

Blood-pressure findings

A subsequent peer-reviewed secondary and post-hoc analysis, published in Hypertension, reported systolic blood pressure fell 10.9 mmHg with CagriSema versus 2.8 mmHg with placebo (diastolic: −5.4 vs. −1.7 mmHg), with a large share of participants on antihypertensive medication able to reduce or stop it. The value of obesity treatment extends beyond the scale to cardiovascular risk.

What REDEFINE 4 found (vs. Zepbound)

On February 23, 2026, Novo Nordisk reported topline results from REDEFINE 4, an open-label, randomized head-to-head trial in 809 adults with obesity comparing CagriSema with tirzepatide 15 mg over 84 weeks. CagriSema delivered 23.0% average weight loss — substantial by any historical standard — but the trial’s primary endpoint was to demonstrate non-inferiority to tirzepatide, and that endpoint was not met: tirzepatide averaged 25.5%. Novo has noted the open-label design as a possible influence and is studying higher CagriSema doses in ongoing trials.

How to read these results honestly

• 23% average weight loss is a strong result in absolute terms; missing a statistical non-inferiority margin does not make a medication ineffective.
• It does mean the best current randomized evidence favors tirzepatide, on average, for maximal weight reduction — replacing the cross-trial guesswork the field previously relied on.
• Open-label head-to-heads carry bias risks in both directions; the peer-reviewed publication will matter.
• Average results are not individual results: tolerability, comorbidities (such as hypertension), access, and cost still drive individual treatment selection.
• The pending FDA decision rests on the placebo-controlled REDEFINE 1 data, which pre-date REDEFINE 4.

BeLite Clinical Perspective

CagriSema remains important: it proves that amylin signaling adds to GLP-1 biology, and if approved it will expand the toolkit — particularly for patients in whom blood-pressure benefit matters. But a new medication does not need to be the market leader to be clinically useful, and no patient doing well on effective, approved therapy should switch or wait based on headlines. Treatment remains a clinical matching problem.

Frequently asked questions

Is CagriSema FDA-approved?

No. The application was filed in December 2025 and is under FDA review, with a decision expected late 2026. It is not available outside clinical trials.

Is CagriSema better than Zepbound?

The REDEFINE 4 head-to-head did not demonstrate non-inferiority to tirzepatide: average weight loss was 23.0% with CagriSema versus 25.5% with tirzepatide at 84 weeks. Individual response, tolerability, and other health effects still vary.

Is CagriSema simply a higher dose of semaglutide?

No. It combines semaglutide with cagrilintide, which acts through the separate amylin pathway.

What should patients do now?

Continue effective, approved treatment when clinically appropriate, and follow emerging evidence without assuming that every new therapy requires a switch.

References

1. Garvey WT, et al. Coadministered cagrilintide and semaglutide in adults with overweight or obesity (REDEFINE 1). N Engl J Med. 2025;393:635–647. doi:10.1056/NEJMoa2502081. https://pubmed.ncbi.nlm.nih.gov/40544433/
2. Verma S, et al. CagriSema reduces blood pressure in adults with overweight or obesity: REDEFINE 1. Hypertension. 2026;83. doi:10.1161/HYPERTENSIONAHA.125.26055. PMID 41328546. https://pubmed.ncbi.nlm.nih.gov/41328546/
3. Novo Nordisk. CagriSema demonstrated 23% weight loss in an open-label head-to-head REDEFINE 4 trial in people with obesity; the primary endpoint was not achieved. News release, February 23, 2026. ClinicalTrials.gov NCT06131437. Press Release
4. Novo Nordisk. Novo Nordisk files for FDA approval of CagriSema. News release, December 18, 2025. Press Release

This week’s News Flash highlights five clinically useful publications appearing in the August literature. The emphasis is on treatment persistence, body composition, oral obesity medications, and practical decisions about treatment goals.

1. Why Do Patients Stop GLP-1 Medications? A New National Survey Adds Real-World Detail

Evidence status: Peer-reviewed national survey

A newly published U.S. survey examined discontinuation of GLP-1 receptor agonists among adults and provides a useful real-world view of why treatment does not always continue as planned. The study is important because persistence is a prerequisite for obtaining and maintaining the benefits seen in clinical trials.

Conclusion of the study: “In this national survey, most US adults who stopped GLP-1 RAs did so within 6 months because of cost, adverse effects, lack of coverage, or having achieved a weight loss goal. Differences in coverage, costs, and sourcing are modifiable targets that may decrease high rates of GLP-1 RA discontinuation.”

Survey data cannot establish cause and effect, and self-reported treatment histories have limitations. Even so, the findings reinforce that discontinuation is not a single clinical phenomenon: affordability, access, adverse effects, treatment expectations, and other practical factors can all influence whether patients remain on therapy.

Belite Commentary

For a weight-management practice, persistence should be treated as a clinical outcome rather than an administrative detail. When treatment is interrupted, the reason matters. A patient stopping because of nausea requires a different strategy from a patient stopping because insurance coverage changed.

The practical implication is to ask about barriers early and repeatedly—before a patient simply disappears from treatment. Dose adjustment, slower escalation, alternative medications, and advance planning for insurance or cost problems may prevent avoidable interruptions.

Primary source: DiStefano MJ, et al. Discontinuation of glucagon-like peptide-1 receptor agonists among US adults: A national survey. J Manag Care Spec Pharm. 2026;32(8):903-910. PMID 42504813. PubMed  |  DOI

2. GLP-1–Based Weight Loss Changes Both Fat and Lean Mass: New Analysis Compares the Available Evidence

Evidence status: Peer-reviewed systematic review and network meta-analysis of randomized trials

A new network meta-analysis compared direct body-composition measurements from randomized trials of GLP-1–based medications in adults with overweight or obesity, with or without type 2 diabetes. The analysis confirms an important point: pharmacologic weight loss is predominantly fat loss, but lean mass also declines.

The exact amount of lean-mass change differed across agents and trials. Because network meta-analysis combines direct and indirect comparisons, the rankings should not be interpreted as if every medication had been tested head-to-head under identical conditions.

Study Conclusion: “GLP-1RAs substantially improve body composition-related excess adiposity, but unfavourable effects on lean mass were observed, particularly at high doses.”

Belite Commentary

The clinical goal is not simply to minimize the number on the scale. It is to reduce excess adiposity while preserving function and as much metabolically useful lean tissue as possible.

For patients—particularly older adults or those starting with low muscle mass—adequate protein intake, resistance exercise, avoidance of unnecessarily severe caloric restriction, and attention to functional strength remain sensible components of GLP-1 treatment. The study does not establish a need for routine body-composition scanning in every patient.

Primary source: Wachiraphansakul N, et al. Comparative Effects of Individual GLP-1 Receptor Agonist-Based Medications on Direct Measurement of Body Composition… Diabetes Obes Metab. 2026;28(8):7018-7038. PMID 42209204. PubMed  |  DOI

3. Oral Semaglutide vs. Orforglipron: An Indirect Comparison Suggests Both Could Become Important Pill Options

Evidence status: Peer-reviewed population-adjusted indirect treatment comparison; not a head-to-head randomized trial

Investigators compared oral semaglutide 25 mg with orforglipron 36 mg using a population-adjusted indirect treatment comparison. Both are oral approaches to obesity treatment, but they differ pharmacologically: oral semaglutide is a peptide GLP-1 receptor agonist, whereas orforglipron is a nonpeptide small-molecule GLP-1 receptor agonist.

Study Conclusion: “In this ITC, oral semaglutide 25 mg was associated with greater body weight loss and fewer discontinuations due to any AEs and due to GI AEs compared with orforglipron 36 mg. These findings provide insight into the comparative effectiveness and tolerability in the absence of head-to-head clinical trials.”

The analysis is useful for anticipating how future oral options might compare, but it is inherently less certain than a randomized head-to-head trial. Differences between the source trials can remain even after statistical adjustment.

Belite Commentary

The larger story is the maturation of oral obesity pharmacotherapy. If effective oral agents become broadly available, some patients who decline injections—or who have difficulty maintaining injectable treatment—may have additional choices.

The comparative numbers should not be used to declare a winner. Direct randomized trials, long-term safety data, regulatory status, dosing instructions, tolerability, cost, and adherence will matter more than an indirect ranking.

Primary source: Michalak W, et al. Oral Semaglutide 25 mg Versus Orforglipron 36 mg in Obesity: A Population-Adjusted Indirect Treatment Comparison. Diabetes Obes Metab. 2026;28(8):7247-7256. PMID 42225305. PubMed  |  DOI

4. Could an Oral Semaglutide Tablet Approach Injectable Wegovy-Level Weight Loss?

Evidence status: Peer-reviewed indirect treatment comparison; not a direct randomized comparison

A separate analysis compared oral semaglutide 25 mg with injectable semaglutide 2.4 mg using data from different clinical-trial populations. The results suggest that high-dose oral semaglutide may be capable of weight loss in the range achieved with injectable semaglutide.

However, this was not a trial in which patients were randomly assigned to the oral versus injectable formulation. Cross-trial differences and statistical assumptions limit how confidently the two formulations can be compared.

Belite Commentary

For patients, the important development is choice. An effective tablet could remove injection reluctance for some people, although oral semaglutide has administration requirements that may affect convenience and adherence.

Study Conclusion: “This ITC suggests that oral semaglutide 25 mg and s.c. semaglutide 2.4 mg offer comparable efficacy for weight management in adults with obesity.”

Until direct comparative evidence is available, clinicians should avoid presenting the oral and injectable formulations as proven equivalents. Effectiveness in routine practice depends on whether patients can take the medication correctly and consistently.

Primary source: Plotkin M, et al. Semaglutide 25 mg Oral Versus Semaglutide 2.4 mg Injectable: An Indirect Treatment Comparison of Weight Loss Outcomes. Diabetes Obes Metab. 2026;28(8):7237-7246. PMID 42225300. PubMed  |  DOI

5. How Much Weight Should a Patient Lose? Experts Argue That the Goal Should Be Health, Not the Lowest Possible Number

Evidence status: Peer-reviewed expert review / clinical perspective

Highly effective obesity medications have created a new clinical question: when should active weight loss stop? A new review examines the concept of healthy weight loss and target weight in an era when medications can produce reductions that were previously difficult to achieve without surgery.

The authors emphasize that a target should not be defined by body weight alone. Body composition, muscle function, nutritional status, age, comorbidities, and the point at which additional loss offers diminishing health benefit all become relevant.

Belite Commentary

This is particularly important as treatment becomes more effective. More weight loss is not automatically better weight loss. A patient who has reached substantial metabolic benefit but is losing strength, lean tissue, or nutritional reserve may need a different goal than a younger patient with substantial residual adiposity.

The practical endpoint should be individualized: meaningful health improvement, sustainable eating and activity, preserved function, acceptable tolerability, and a maintenance strategy—not simply pursuit of the lowest achievable scale weight.

Primary source: Bosy-Westphal A, et al. Defining Healthy Weight Loss and Target Weight in the Era of Highly Effective Treatment of Patients With Obesity. J Cachexia Sarcopenia Muscle. 2026;17(4):e70334. PMID 42455525. PubMed  |  DOI

Belite Clinical Takeaway

This week’s literature emphasizes a transition in obesity medicine from asking only “How much weight can this drug produce?” to asking more clinically useful questions: Can the patient stay on treatment? What is happening to fat and lean tissue? Would an oral option improve adherence? And when has a patient lost enough weight to shift from active loss to maintenance?

BeLite can help patients translate emerging obesity-medicine evidence into an individualized plan that considers efficacy, tolerability, nutrition, muscle preservation, long-term maintenance, and access.BeLite Medical Center has provided physician-supervised medical weight management in Fairfax, Virginia since 1995. Our clinic offers in-person medical supervision — with the ability to adjust medications and monitor your progress in real time — that fully virtual services cannot match.Booking appointments is simple with our online scheduling portal, available 24/7. You can also call or text us at (703) 359-9200, or email belitemed@gmail.com. We offer free consultations for new patients — if you choose not to enroll, there is no charge. We serve patients across Virginia, Maryland, Washington D.C., the DMV area, Pennsylvania, and West Virginia. Patients do not sign treatment contracts and can stop coming at any time

Medical Disclaimer

This blog post is provided for informational purposes only and does not constitute medical advice, diagnosis, or treatment. It is not intended to substitute for consultation with a licensed healthcare provider. Readers should not use this information to diagnose or treat a medical or health condition without consulting an appropriately qualified healthcare professional. Any reliance on the information in this blog is at the reader’s own risk. Individual weight loss results vary based on personal health status and adherence to medical advice. No doctor-patient relationship is created by accessing or reading this content.